Status:
COMPLETED
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
Lead Sponsor:
GlaxoSmithKline
Conditions:
Carcinoma, Hepatocellular
Eligibility:
All Genders
21+ years
Phase:
PHASE1
Brief Summary
Liver cancer is a good target for anti-angiogenic treatments such as pazopanib. The effect of pazopanib in patients with liver cancer are unknown. This study is designed to evaluate the safety, tolera...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosis of advanced liver cancer adequate bone marrow, liver and kidney function
- Any local therapy for tumor must have been completed at least 4 weeks prior to enrolling in study
- Exclusion criteria:
- Pregnant or breastfeeding
- Any serious or unstable medical or psychiatric conditions
- History of metastases to central nervous system
- History of ulcer, inflammatory bowel disease or disease of the gut
- History of HIV, or uncontrolled infection
- Have had a cardiac condition or stoke during the past 6 months
- High blood pressure
- Have had a blood clot during the past 6 months
- History of bleeding blood vessels
Exclusion
Key Trial Info
Start Date :
December 6 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 8 2009
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00370513
Start Date
December 6 2006
End Date
April 8 2009
Last Update
November 17 2017
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
San Francisco, California, United States, 94115
2
GSK Investigational Site
Hong Kong, Hong Kong
3
GSK Investigational Site
Taipei, Taiwan, 100